Marksans announces receipt of marketing authorization for Levonorgestrel 1.5 mg Tablets
From UK MHRA
Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA.
Levonorgestrel, also known as the morning-after pill, is a first-line oral emergency contraceptive pill. It is to be used within 72 hours of unprotected sexual intercourse or when a presumed contraceptive failure has occurred
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Aug 02 2024 | 4:12 PM IST